Phase 2 Leukaemia Trial, Recruiting NCT07512700 Sponsor: Chinese PLA General Hospital Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT07512700
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily and have signed a written consent form (or whose legal guardian has signed on their behalf), and who are willing to follow all study procedures
  • People aged 14 to 60 years at the time of screening, of any gender
  • People who have been diagnosed with acute monocytic leukemia (a specific type of blood cancer, classified according to 2016 WHO standards), not including a subtype called acute promyelocytic leukemia
  • People with no history of severe allergic reactions
  • People whose liver is functioning within acceptable ranges, based on specific blood test results (ALT, AST, and bilirubin levels — confirm with trial site)
  • People whose kidneys are functioning within acceptable ranges, based on a specific blood test (serum creatinine level — confirm with trial site)
  • People who do not have an uncontrolled infection or a severe psychiatric (mental health) disorder
  • People who are reasonably well and mobile, rated 0–3 on a standard health scale used by doctors (confirm with trial site), with a life expectancy of at least 4 months

Who may not be able to join:

  • People who are known to be allergic to, or medically unsuitable for, any of the study drugs
  • People who are pregnant or currently breastfeeding
  • People who have an active infection at the time of joining
  • People with a history of long-term heavy smoking or alcohol use that could affect how study results are measured
  • People with a psychiatric illness or other condition that would make it difficult to give informed consent or follow study procedures
  • People who have had major surgery on an organ within 6 weeks before enrolling in the trial
  • People whose liver or kidney function test results fall outside the acceptable ranges set by the trial (confirm with trial site)
  • People whom the trial investigator considers unsuitable for any reason, such as concerns about ability to follow the study requirements or substance use

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Liping Dou, Doctor, Chinese PLA General Hospital

Phone: +8613681207138

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chinese PLA General Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
30 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Composite Complete Remission Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov